An economic evaluation of universal infant vaccination against hepatitis B virus using a combination vaccine (Hib-HepB): A decision analytic approach to cost effectiveness

Australian and New Zealand Journal of Public Health

Volumn 25, Issue 3, 2001, Pages 222-229

  Harris, Anthony ^a,c   Yong, Karen ^a   Kermode, Michelle ^b  

^a MONASH UNIVERSITY   (Australia)

^b CSL LIMITED   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; LAMIVUDINE; UNCLASSIFIED DRUG;

ACUTE DISEASE; ANALYTIC METHOD; ARTICLE; BUDGET; CASE REPORT; CHILD; CHRONIC HEPATITIS; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; ECONOMIC EVALUATION; EPIDEMIOLOGICAL DATA; HEALTH CARE COST; HEALTH SURVEY; HEPATITIS B; HEPATITIS B VIRUS; HIGH RISK PATIENT; HUMAN; INFANT; INVESTMENT; MAJOR CLINICAL STUDY; MEDICAL EXPERT; MODEL; PATIENT COMPLIANCE; PREDICTION; VACCINATION;

EID: 0034945857     PISSN: 13260200     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1467-842X.2001.tb00566.x     Document Type: Article

References (23)

1. The incidence of hepatitis B infection in Australia: An epidemiological review
2. Expanded programme on immunisation
3. Global programme for control of hepatitis B infection
4. Update on diagnosis, management and prevention of hepatitis B virus infection
5. Hepatitis B immunisation rates among infants in ethnic groups with high prevalences of hepatitis B surface antigen carriers
6. Hepatitis B immunisation coverage of infants born to chronic carrier mothers in Victoria
7. Coverage of children immunised
8. The Markov process in medical prognosis
9. Clinical and economic impact of a combination haemophilus influenzae and hepatitis B vaccine
10. Should Canada and the United States universally vaccinate against hepatitis B?: A cost-effectiveness analysis
11. Safety and immunogenicity of a bivalent Haemophilus influenzae type b/hepatitis B vaccine in healthy infants
12. Hepatitis B virus infection among children born in the United States to Southeast Asian refugees
13. The cost effectiveness of alpha interferon in the treatment of chronic hepatitis
14. Recommendations of the panel on cost-effectiveness in health and medicine
15. Discounting and health benefits
16. Towards the eradication of hepatitis B in Australia
17. National, state, and urban area vaccination coverage levels among children aged 19-35 months: United States, 1996
18. Hepatitis B in urban Australian school children: No evidence of horizontal transmission between high-risk and low-risk groups